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Get Real!Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsI was recently interviewed for a research projectabout what type of clinical trials get performedand which ones get published. The discussion
was to be speciﬁcally about “real-world experience”
or “real-world evidence.” I bristled at the term that I
have grown to dislike very much, and I told the inter-
viewer as much. The interviewer redeﬁned the sub-
ject so that I would stop ranting about the term and
changed it to “any studies that are not randomized
trials.” The purpose of this survey of editors seems
to be to understand the signiﬁcance of nonrandom-
ized studies, the strengths and weaknesses of non-
randomized studies, whether authors and reviewers
are given speciﬁc guidelines for preparing and evalu-
ating such studies, and, not so subtly implied,
whether there is editorial bias against publishing
nonrandomized studies.
The strengths of randomized trials are well known
and are primarily the elimination of signiﬁcant base-
line variables, either recognized or nonrecognized.
Without randomization, unrecognized confounding
variables have to be assumed and accounted for. Does
this mean nonrandomized studies are lacking val-
idity? Clearly not, nor can we assume that all ran-
domized trials are valid. They can, despite
randomization, suffer from poor design and methods,
inadequate power or from studying highly reﬁned
subgroups because exclusions result in a residual
population that does not reﬂect the patients to which
the conclusions are applied. Some questions cannot
be answered without randomized trials, but some
randomized trials cannot answer the questions.
After I got the interviewer away from the “real
world,” I discussed the kind of nonrandomized clin-
ical studies that we see in interventional cardiology.
They range from single-center retrospective obser-
vations to well-planned prospective registries with
structured follow-up and often independent out-
comes adjudication. Not infrequently, we see largeregistries addressing issues that have evidence
already generated by randomized trials. What value
do they have? The randomized trials may be targeted
to a selected population but a large registry that is
more inclusive can inform the answer if it is in the
same direction as the randomized study. Therapies
that change can be evaluated by nonrandomized
registries collecting sequential data before and after a
change. Post-approval surveillance of new devices
can provide critical information regarding rare oc-
currences that went undetected in randomized trials.
I wondered about some of the questions I was
asked. Do we need instructions to authors about what
makes a valuable nonrandomized study? Do we need
instructions to reviewers? The same general guide-
lines for priority apply for randomized as well as
nonrandomized studies. Is it new? Is it true? And, is it
relevant? Novelty (new) probably applies to both
types of studies in the same way. Validity (true) de-
pends on the ability to understand the strengths and
weaknesses of the study design and execution, and
they differ between the types of comparisons. Clinical
importance (relevance) sometimes is judged on how
results apply to the broad population or to speciﬁc
subsets, differences that may be more appropriate to
randomized or nonrandomized studies.
This interview about the value of nonrandomized
studies caused me to reﬂect on what we are doing at
JACC: Cardiovascular Interventions. We accept more
studies that can be classiﬁed as nonrandomized than
randomized so we obviously see value in these. I am
not sure that author or reviewer instructions are
necessary, but there is a great deal written about
structuring observation studies, registries, and pop-
ulation studies. Major strengths of prospective reg-
istries are the size and inclusiveness, as well as clear
deﬁnitions and organized follow-up. A lot of excellent
papers have come from registries that have some of
these features such as the New York State Registry,
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205the NCDR (National Cardiovascular Data Registry),
the SCAAR (Swedish Registry), and the National
Health System of the United Kingdom. These study
large population groups, but they may not allow as
complete an evaluation as prospective targeted reg-
istries with mandated clinical follow-up would. The
PARTNER (Placement of Aortic Transcatheter Valve
Trial) registry and the French TAVI (Transcatheter
Aortic Valve Implantation) registry and others come
to mind.
Will nonrandomized studies play an increasing role
in generating evidence? Most think so. Large ran-
domized trials are getting very expensive. Collection
of massive amounts of data for other purposes is
becoming much cheaper. Therefore, it is attractive to
try to generate evidence from data already being
collected (i.e., administrative data). There are several
problems using billing data to answer clinical ques-
tions. The data from billing codes is notoriously
incomplete, and although it may serve a purpose foravoiding billing errors, it is far from avoiding clinical
errors. Another approach to performing trials at lower
cost was the SAFE PCI-For Women (Study of Access
Site for Enhancing PCI for Women) trial (1). They used
NCDR baseline data to identify and enroll subjects for
a randomized trial.
Innovative approaches to research will clearly
evolve and cost containment will be a major consid-
eration. Some questions will be answerable only by
randomization whereas others will provide answers
through well-performed nonrandomized studies.
Neither of these approaches are “outside the real
world,” and neither apply perfectly to the “real pa-
tient.” Let’s drop “real world” and describe our
studies more precisely.
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